Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q1 FY27 results · Apr–Jun 2026
Onesource Specialty Pharma reported revenue from operations of ₹449.02 crore (up 37.2% from Q1 FY26) and net profit of ₹25.00 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 449.02 | 327.27 | +37.2% | 428.22 | +4.9% |
| Other income | 3.80 | 5.27 | −27.8% | 2.09 | +81.7% |
| Total income | 452.82 | 332.54 | +36.2% | 430.31 | +5.2% |
| Profit before tax | 20.29 | (4.40) | Turned profit | (0.29) | Turned profit |
| Net profit for the period | 25.00 | (0.19) | Turned profit | 4.60 | +443.8% |
| EPS, basic (₹) | 2.18 | (0.02) | Turned profit | 0.40 | +445.0% |
| Net margin (%) | 5.6 | -0.1 | 1.1 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 446.47 | 321.01 | +39.1% | 418.96 | +6.6% |
| Other income | 3.79 | 5.25 | −27.9% | 2.09 | +80.9% |
| Total income | 450.26 | 326.27 | +38.0% | 421.06 | +6.9% |
| Profit before tax | 51.23 | 24.82 | +106.4% | 21.48 | +138.5% |
| Net profit for the period | 51.23 | 24.82 | +106.4% | 21.48 | +138.5% |
| EPS, basic (₹) | 4.47 | 2.17 | +106.0% | 1.87 | +139.0% |
| Net margin (%) | 11.5 | 7.7 | 5.1 |
Consolidated
- Filed with BSE
- 24 Jul 2026, 19:27 IST
- Board meeting
- 24 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jul 2026, 19:27 IST
- Board meeting
- 24 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE